Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 919-932
Open Access | Times Cited: 19

Showing 19 citing articles:

Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
Carlo Alberto Vignoli, Luigi Gargiulo, Luciano Ibba, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access | Times Cited: 2
Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy
Jonathan I. Silverberg, Thomas Bieber, Amy S. Paller, et al.
Dermatology and Therapy (2025)
Open Access | Times Cited: 2
Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options
Carlo Alberto Maronese, Mario Valenti, Chiara Moltrasio, et al.
Journal of Investigative Dermatology (2024) Vol. 144, Iss. 11, pp. 2364-2376
Closed Access | Times Cited: 9
Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives
Ewa Alska, Dariusz Łaszczych, Katarzyna Napiórkowska-Baran, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1079-1079
Open Access | Times Cited: 1
Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis
Maddalena Napolitano, Luciano Foggia, Cataldo Patruno, et al.
Clinical and Experimental Dermatology (2024) Vol. 49, Iss. 10, pp. 1232-1234
Open Access | Times Cited: 4
Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study
Luigi Gargiulo, Luciano Ibba, Matteo Bianco, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 4
Dual Relief: How Atopic Dermatitis Treatments Affect Alopecia Areata—A Small Retrospective Cohort Study
D Brănişteanu, Antonia-Elena Huțanu, Daniel Brănișteanu, et al.
Diagnostics (2025) Vol. 15, Iss. 5, pp. 520-520
Open Access
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study
Francesco Leo, Michela Ortoncelli, Ruggero Cascio Ingurgio, et al.
American Journal of Clinical Dermatology (2025)
Open Access
Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United States
Jonathan I. Silverberg, Peter J. Anderson, Joseph C. Cappelleri, et al.
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Open Access
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis
Yan Zhao, Litao Zhang, Liming Wu, et al.
Dermatitis (2025)
Closed Access
Five‐year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real‐world study
Luigi Gargiulo, Silvia Ferrucci, Luciano Ibba, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Closed Access
Comparative Real-World Analysis of Baseline Demographic Characteristics and Comorbidities in Atopic Dermatitis Patients Initiating Biologics Versus JAK Inhibitors
Álvaro Prados‐Carmona, F.J. Navarro‐Triviño, Husein Husein‐ElAhmed, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1291-1291
Open Access
New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review
M.A. Bianco, F D’Oria, Costanza Falcidia, et al.
Medicina (2025) Vol. 61, Iss. 4, pp. 631-631
Open Access
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study
Luciano Ibba, Costanza Falcidia, S. Di Giulio, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 9, pp. 2953-2953
Open Access
Atopic dermatitis: pathogenesis and therapeutic intervention
Chengcheng Yue, Hong Zhou, Xiaoyan Wang, et al.
MedComm (2024) Vol. 5, Iss. 12
Closed Access | Times Cited: 2
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis)
Luigi Gargiulo, Luciano Ibba, Ângela Alfano, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 1
Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system
Zhu Zhou, Mingjuan Liu, Hanlin Zhang, et al.
Expert Opinion on Drug Safety (2024), pp. 1-8
Closed Access
Utilisation des médicaments systémiques dans le traitement de la dermatite atopique modérée à sévère de l’adulte
Jean‐David Bouaziz
Annales de Dermatologie et de Vénéréologie - FMC (2024) Vol. 4, Iss. 5, pp. S22-S26
Closed Access
The role of nemolizumab in the treatment of atopic dermatitis for the adult population
Stuti Prajapati, Joseph P Flemming, Danyaal Khan, et al.
Immunotherapy (2024) Vol. 16, Iss. 14-15, pp. 925-935
Closed Access
Clearance of Darier disease lesions in a patient with concomitant atopic dermatitis treated with abrocitinib
M.A. Bianco, S. Di Giulio, Luciano Ibba, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Open Access
Page 1

Scroll to top